Could you discuss the objectives of your research into congenital hydrocephalus, more commonly known as water on the brain, and explain how your background has prepared you for this line of investigation?

We wish to understand how this disease arises and might be prevented and more effectively treated. This research came about through a confluence of scientific and medical experiences over the last three decades, which included basic science studies on the foetal brain, cellular and molecular biology, receptor pharmacology, knock-out technologies and drug discovery. All of these elements were used for the initial discovery of a new mechanism for hydrocephalus, and are being used in current research efforts.

How will your team overcome the treatment challenges posed by the condition?

As a receptor-mediated phenomenon, it is possible that hydrocephalus could be prevented, or at least attenuated, by drugs targeting the involved receptors. Such medical intervention has clear potential benefits over neurosurgical draining of the cerebrospinal fluid (CSF), which is itself subject to complications. Notably, G protein-coupled receptors are the target for nearly half of human medicines currently on the market, so the feasibility of producing such an agent is reasonable.

Can you elucidate the methodologies you are using to determine receptor selectivity of physiological and pathophysiological functions affecting the brain?

Lipids in general are messy and sticky, making their analyses problematic, especially relative to receptors. The literature is filled with erroneous conclusions on lysophospholipid (LP) receptor identification, functions and so forth, reflecting difficulties in handling lipids and, before receptor identification, interpretations on how these lipids in fact worked. The introduction of heterologous expression systems – cell lines that did not respond to a lipid unless made to express a specific receptor – allowed for the unambiguous identification of receptors. These systems worked in combination with mouse knock-out techniques and classical ligand binding strategies which, by themselves, are
HYDROCEPHALUS IS A condition whereby cerebrospinal fluid accumulates inside the ventricles or cavities of the brain, causing pressure to build. Congenital hydrocephalus, a version of the illness that affects children before or around birth, is one of the most common neurological disorders in infants and young children. Affecting one in 1,000 newborns, the most recognisable characteristic of the disease is the rapid expansion it causes in the head of infant patients, whose skulls are still malleable. The cause of the disorder is usually genetic, but it can be acquired, and early warning signs include poor feeding and vomiting.

If it strikes within the first three years of life, before the cranial bones fuse, and is left untreated, hydrocephalus can seriously disrupt the development of the head – but even with treatment, there are other sequelae that cannot be alleviated. In current practice there is no cure for the condition, and even palliative treatments fail to counteract the psychiatric and neurological impact of the extreme pressure. As it stands, the front-line treatment for hydrocephalus is the neurosurgical removal of excess fluid – a process that, in itself, carries risks. In serious and ongoing cases, a cerebral shunt can be installed, again increasing patient vulnerability to complications.

TWEAKING TREATMENTS

Less invasive and more effective preventive measures for curtailling congenital hydrocephalus are desperately needed but, to date, researchers remain perplexed by this enigmatic condition. The causative molecular mechanisms behind presentation of the disease, as with many neurological disorders, are mysterious, and with so many molecular pathways and receptor networks already known to be active in the developing and adult brain, finding an appropriate target is like looking for a needle in a haystack. A newly discovered form of molecular signalling found to be prevalent in the brain, however, has spurred research into this disease.

The human brain, when water is discounted, is composed mostly of lipids. These molecules, which are sticky and difficult to work with, also make up the lipid bilayer that is fundamental to the walls of cells, and are in general an important building material for the body at a molecular level. For more than 50 years, evidence suggested that lipids also play a role in the production of extracellular effects, but it was not until 1996 that scientists identified the first lysophospholipid (LP) receptor, and demonstrated that LPs can act as receptor-mediated signalling molecules. Dr Jerold Chun, Professor of Molecular and Cellular Neuroscience at The Scripps Research Institute in California, led this initial demonstration, and today his research focuses on the ways in which LP biology could aid medicine, particularly helping patients who suffer from neurological disorders.

THE REVOLUTIONARY RECEPTOR

In the mid-1990s, Chun and his collaborators, then at the University of California, San Diego were looking for genes active during foetal brain development and found ventricular zone gene 1 (VZG-1), a G protein-coupled receptor of unknown function, activated by an unknown ligand. The researchers were working with neuron-like cells they had specifically produced from the brain at a time when most labs were expressing orphan receptors in more convenient cell types. Because of this, they found that VZG-1-bearing cells reacted strangely when placed in the culture medium. The medium
**INTELLIGENCE**

**LYSOPHOSPHOLIPID MECHANISMS IN CONGENITAL HYDROCEPHALUS**

**OBJECTIVE**

To understand how congenital hydrocephalus arises and can be prevented by investigating lysophospholipid mechanisms, in order to develop an effective treatment for the condition and other neurological disorders.

**KEY COLLABORATORS**

Dr Yun Yung, The Scripps Research Institute, USA
Dr Jill Morris, The Scripps Research Institute, USA

**ACKNOWLEDGMENTS**

Paul Gross, Hydrocephalus Association, USA
Dr Story Landis, National Institute of Neurological Disorders and Stroke, USA
Helen L Dorris, Dorris Neuroscience Center, USA

**FUNDING**

National Institutes of Health (NIH) • National Institute of Neurological Disorders and Stroke

**CONTACT**

Dr Jerold Chun
Professor
Molecular and Cellular Neuroscience
Dorris Neuroscience Center
The Scripps Research Institute
10550 North Torrey Pines Road
DNC-118
La Jolla, California, 92037
USA
T +1 858 784 8410
E jchun@scripps.edu
www.scripps.edu/chun/index.html

**HOT TOPIC**

Over the intervening years, interest in this field has grown exponentially. Today, Chun's discovery has led to the identification of around 15 receptors in the LP family, a number that is still growing. The contribution to basic biological science has been huge, but for the California researchers this was merely the beginning of their work. As they had initially suspected, this class of receptor has a multipurpose impact on neural cells in the developing brain, and also plays a role in defining brain cell morphology and electrophysiology, as well as processes such as proliferation, myelination, organisation and even cell behaviour.

This diversity of function makes LP receptors an extremely promising target for novel drugs aimed at treating neurological disorders such as hydrocephalus and multiple sclerosis (MS). In 2010, fingolimod was approved by the US Food and Drug Administration (FDA) and became the first oral treatment for relapsing forms of MS. The drug is thought to work by trapping lymphocytes within the lymph node so that they are unable to contribute to inflammation and the destruction of myelin within the brain. The chemical itself looks very much like an LP in structure and achieves its protective effect by interacting with four species of LP receptor. Its mode of action is dissimilar to any previous therapeutic mechanisms towards preventing the accumulation of cerebrospinal fluid and the symptoms of hydrocephalus. Chun and his group hypothesised that LPA found in these blood fractions was the cause and, when they repeated the experiment with an injection of LPA in solution, the murine subjects developed severe symptoms. The final step of the experiment was to repeat the process a final time using murine models that did not express the necessary LP receptors, and the fact that they were unable to produce symptoms in these mice using the same methods suggests that this may be a possible medical route to treatment for hydrocephalus. Additionally, delivering an LPA receptor antagonist into the brain at the time of hydrocephalus appeared to also prevent its development, which provides a proof of concept for possible future therapy.

**TRIAL AND SUCCESS**

In the same year, his lab released the results of a study into the causes of hydrocephalus. Using mouse models created for the purpose, the team injected either serum, plasma or red blood cells directly into the cerebral ventricles of the developing rodent. Because bleeding into the ventricles in the foetal brain appears to be one of the causative factors behind hydrocephalus, the researchers were keen to gauge what components of blood caused the problem. The mice were then observed at several time points following injection to investigate their progress.

Red blood cell injections had no impact on development – but the presence of either plasma or serum in the ventricles precipitated the accumulation of cerebrospinal fluid and the symptoms of hydrocephalus. Chun and his group hypothesised that LPA found in these blood fractions was the cause and, when they repeated the experiment with an injection of LPA in solution, the murine subjects developed severe symptoms. The final step of the experiment was to repeat the process a final time using murine models that did not express the necessary LP receptors, and the fact that they were unable to produce symptoms in these mice using the same methods suggests that this may be a possible medical route to treatment for hydrocephalus. Additionally, delivering an LPA receptor antagonist into the brain at the time of hydrocephalus appeared to also prevent its development, which provides a proof of concept for possible future therapy.

**BETTERING THE BRAIN**

“We would dearly like to identify tractable therapeutic mechanisms towards preventing disease – or at least reducing its severity,” Chun remarks, and today it seems likely that this dream is finally within reach. The group has been responsible for elucidating a crucial class of receptor and, alongside Chun's more recent efforts towards clinical solutions, this achievement stands as a lasting legacy in the field.